BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment

BioInvent, known for its innovative cancer immunotherapies, is expanding its partnership with MSD to test BI-1607 in combination with ipilimumab and KEYTRUDA in a phase II trial for metastatic melanoma. The phase II study aims to enhance the efficacy of these existing treatments while reducing toxicity, potentially offering a more tolerable and effective treatment regimen.

Read the article at biostock.se:

BioInvent and MSD to evaluate new metastatic melanoma treatment

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/